Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111 in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

Authors :: Hafsah Nabi
Bente Glintborg
Anne Gitte Loft
Oliver Hendricks
Jens Kristian Pedersen
Søren Andreas Just
Ahmed, R.
Danebod, K.
Heidi Munk
Ada Colic
Asta Linauskas
Jensen, D.
Christensen, L.
Manilo, N.
Niels Lomborg
Kristensen, S.
Frank Mehnert
Niels Steen Krogh
Merete Lund Hetland
Source :: University of Southern Denmark, Nabi, H, Glintborg, B, Loft, A G, Hendricks, O, Pedersen, J K, Just, S A, Ahmed, R, Danebod, K, Munk, H L, Colic, A, Linauskas, A, Jensen, D V, Christensen, L B, Manilo, N, Lomborg, N, Kristensen, S, Mehnert, F, Krogh, N S & Hetland, M L 2021, ' Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry ', Scandinavian Journal of Rheumatology, vol. 50, no. Suppl. 130, pp. 14-15 ., Nabi, H, Glintborg, B, Loft, A G, Hendricks, O, Pedersen, J K, Just, S A, Ahmed, R, Danebod, K, Munk, H L, Colic, A, Linauskas, A, Jensen, D, Christensen, L, Manilo, N, Lomborg, N, Kristensen, S, Mehnert, F, Krogh, N S & Hetland, M L 2021, ' Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111 in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry ', EULAR 2021 Virtual Congress, 02/06/2021-05/06/2021 .

Database :: OpenAIRE
Journal :: University of Southern Denmark, Nabi, H, Glintborg, B, Loft, A G, Hendricks, O, Pedersen, J K, Just, S A, Ahmed, R, Danebod, K, Munk, H L, Colic, A, Linauskas, A, Jensen, D V, Christensen, L B, Manilo, N, Lomborg, N, Kristensen, S, Mehnert, F, Krogh, N S & Hetland, M L 2021, ' Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry ', Scandinavian Journal of Rheumatology, vol. 50, no. Suppl. 130, pp. 14-15 ., Nabi, H, Glintborg, B, Loft, A G, Hendricks, O, Pedersen, J K, Just, S A, Ahmed, R, Danebod, K, Munk, H L, Colic, A, Linauskas, A, Jensen, D, Christensen, L, Manilo, N, Lomborg, N, Kristensen, S, Mehnert, F, Krogh, N S & Hetland, M L 2021, ' Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111 in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry ', EULAR 2021 Virtual Congress, 02/06/2021-05/06/2021 .
Accession number :: edsair.dedup.wf.001..689b1e481caf867be11a893d06b5bf42

Tools